Clinical Trials for Multiple Myeloma
Multiple myeloma is a cancer of plasma cells -- a type of white blood cell that normally produces antibodies. It affects the bone marrow and can cause bone pain, fatigue, kidney damage, and a weakened immune system. Treatment has advanced significantly in recent years, and clinical trials have been central to every major improvement in outcomes.
New treatment combinations, novel agents, and cellular therapies are all being studied in active trials right now. If you are newly diagnosed, have relapsed after prior treatment, or are facing a coverage denial, clinical trials may offer meaningful access to advanced care.
According to the Multiple Myeloma Research Foundation, approximately 35,000 Americans are diagnosed with multiple myeloma each year.
What Types of Trials Are Available?
Triplet and quadruplet regimen trials are studying combinations of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies -- building on the combinations that have become standard of care and asking whether adding a fourth agent improves outcomes. Antibody-drug conjugate (ADC) trials study newer agents that deliver chemotherapy directly to myeloma cells using a targeted antibody. CAR-T cell therapy trials are among the most significant developments in myeloma. CAR-T involves re-engineering your own immune cells to attack myeloma. These trials are often conducted at specialized academic centers and have shown remarkable results in relapsed/refractory disease. Bispecific antibody trials study a newer class that activates your T cells to attack myeloma cells -- another highly active area with promising early results. Maintenance therapy trials study whether longer-term treatment after initial response reduces relapse rates.Search ClinicalTrials.gov for currently recruiting trials.
Am I Eligible?
Common eligibility factors for multiple myeloma trials include:
- Confirmed multiple myeloma diagnosis (distinct from smoldering myeloma or MGUS)
- Number of prior lines of therapy -- many trials have specific requirements
- Prior exposure to specific drug classes (proteasome inhibitors, IMiDs, anti-CD38 antibodies)
- Adequate bone marrow, kidney, and liver function
- Performance status
- No active CNS involvement (in most trials)
Trials for relapsed or refractory myeloma are particularly active. If you have received two or more prior lines of therapy, you may qualify for a wide range of advanced trials, including CAR-T and bispecific antibody studies.
Talk to your hematologist-oncologist to evaluate your current eligibility. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
High-cost myeloma treatments -- including daratumumab (Darzalex), bortezomib (Velcade), lenalidomide (Revlimid), and newer agents -- are commonly subject to prior authorization and coverage challenges. If your specialist has prescribed a therapy and your insurer has denied it, you have the right to appeal, and you have the right to explore trial options simultaneously.
CAR-T and bispecific antibody trials, in particular, offer access to treatments that are either recently approved or still investigational -- and in a trial, those treatments are provided at no cost.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for multiple myeloma free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find multiple myeloma trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Darzalex or Revlimid?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Darzalex or Revlimid or similar medications.